Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared on X a recent paper published in ACS Journals:
“Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile.”
Authors: Hagop Kantarjian et al.
See more posts by Hagop Kantarjian on OncoDaily.